EGFR and renal cell carcinoma: Furthermore, combination of EGFR-CAR-NK-92 with cabozantinib showed a synergistic therapeutic effect against renal cell carcinoma (RCC) cell lines and in human RCC xenograft models, highlighting the potential of combining CAR-NK cells and chemotherapy as a promising strategy for the treatment of solid tumors (135).